AESCULAPIUS Farmaceutici

AESCULAPIUS Farmaceutici, also known simply as AESCULAPIUS, is an Italian pharmaceutical company. As a pharmaceutical company, its core business concerns medicinal products. Its headquarters are located in Italy, placing it within the European pharmaceutical market. While specific product lines are not detailed in the available sources, the company operates as a supplier of pharmaceutical goods. The organisation serves healthcare providers and patients who rely on its medications for treatment. Its activities are subject to the regulatory frameworks governing pharmaceuticals in Italy and the broader EU.

In February 2023, AESCULAPIUS Farmaceutici became the target of a ransomware attack carried out by the RansomHouse group. The attackers compromised the company’s IT infrastructure, exfiltrating sensitive data before encrypting systems. RansomHouse subsequently published the stolen information on its darknet leak site after the victim reportedly refused to meet ransom demands. The incident exemplifies a double extortion strategy, combining data encryption with threatened public disclosure. According to the ransomware group’s claim, the affected organisation had approximately twenty‑five employees and an annual revenue of about 5.4 million US dollars. The attack disrupted normal operations and exposed internal directories containing various company data. No official statement regarding the breach was published on the company’s website at the time of reporting, despite the leak of the compromised materials. This event highlights the cybersecurity risks faced by mid‑size pharmaceutical firms in the current threat landscape.